<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Food and Drug Administration Monoclonal antibodies United States Public Health Service Propylthiouracil MedWatch Zicam Adverse event Insulin detemir Infliximab Medicine Pharmacology Pharmaceutical industry |
Add to Reading List |
FDA Patient Safety News: Show #89, August 2009 | Print Form Alabama Board of Medical Examiners P.O. Box 946, Montgomery, ALOffice-Based Surgery Adverse Event Report FormDocID: 1vm7X - View Document |
| Washington University in St. Louis Institutional Biological & Chemical Safety Committee Policy on Severe Adverse Event Reporting for Human Gene Therapy Trials As outlined in Section IV-B-2-b-(1) of the NIH Guidelines forDocID: 1vily - View Document |
| National Action Plan for Adverse Drug Event PreventionDocID: 1v1KN - View Document |
| Microsoft Word - FINAL-Formatted-University Adverse Weather and Emergency Event Policy -effDocID: 1uZd2 - View Document |
| National Action Plan for Adverse Drug Event PreventionDocID: 1uxaR - View Document |